PAT-SM6 / Patrys - LARVOL DELTA

Targeting GRP78 with PAT-SM6 disrupts glioblastoma metabolism and tumor growth (SNO 2025) - "PAT-SM6 selectively targets GRP78 to induce apoptosis, disrupt glycolysis, and inhibit migration in GBM, leading to decreased tumor growth, especially when GRP78 is genetically ablated. Combination studies with temozolomide and GRP78 biomarker validation are underway to improve therapeutic strategies against GBM."

Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ATF6 • CALR • CASP1 • CASP12 • GAPDH • HSPA5 • PKM • VIM

Targeting GRP78 with PAT-SM6 disrupts glioblastoma metabolism and tumor growth (WFNOS 2025) - "PAT-SM6 selectively targets GRP78 to induce apoptosis, disrupt glycolysis, and inhibit migration in GBM, leading to decreased tumor growth, especially when GRP78 is genetically ablated. Combination studies with temozolomide and GRP78 biomarker validation are underway to improve therapeutic strategies against GBM."

Brain Cancer • Glioblastoma • Glioma • Solid Tumor • ATF6 • CALR • CASP1 • CASP12 • GAPDH • HSPA5 • PKM • VIM

Patrys’ anti-cancer drug shown to be safe in the treatment of melanoma (Proactiveinvestors) - Patrys has completed the treatment of pts in the P1 trial of its PAT-SM6 anti-cancer antibody for the treatment of melanoma with the highest dose levels shown to be safe; Patrys expects the full trial data to be available by the end of March 2012

Anticipated P1 data • Melanoma

Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target. (PubMed, Cancers (Basel)) - "As csGRP78 is found to mainly configur as an external peripheral protein on cancer cell surface, how it can transmit death signals to the cytoplasmic environment remains enigmatic. With the recent encouraging results from the natural csGRP78 targeting pro-apoptotic monoclonal antibody PAT-SM6 in early-stage cancer clinical trials, the potential to develop a novel class of anticancer therapeutics targeting csGRP78 is becoming more compelling."

Journal